Elevation Oncology, Inc. (ELEV) Bundle
Who Invests in Elevation Oncology, Inc. (ELEV) and Why?
Who Invests in Elevation Oncology, Inc. (ELEV) and Why?
Understanding the investor profile of Elevation Oncology, Inc. involves examining the key types of investors, their motivations for investing, and the strategies they employ.
Key Investor Types
- Retail Investors: Individual investors who buy and sell securities for their personal accounts. As of September 30, 2024, retail investors owned approximately 30% of the total shares outstanding.
- Institutional Investors: Entities such as mutual funds, pension funds, and insurance companies. They held about 60% of the shares, with notable investments from firms like Vanguard and BlackRock.
- Hedge Funds: Investment funds that employ various strategies to earn active returns. Hedge funds accounted for roughly 10% of the total shares outstanding, with a focus on short-term trading strategies.
Investment Motivations
Investors are attracted to Elevation Oncology for several reasons:
- Growth Prospects: The company is currently advancing its lead product candidate, EO-3021, which targets specific cancer therapies. Analysts project a potential market size of $5 billion by 2030 for therapies targeting Claudin 18.2.
- Market Position: As a clinical-stage oncology company, it holds a unique position in the market with a focus on unmet medical needs, which appeals to growth-oriented investors.
- Research and Development Pipeline: Investors are drawn to the company’s robust pipeline, including EO-3021 and other candidates, expected to enter clinical trials in the coming years.
Investment Strategies
Investors employ various strategies when investing in Elevation Oncology:
- Long-Term Holding: Many institutional investors adopt a long-term strategy, anticipating significant returns as the company progresses through clinical trials and potentially secures FDA approvals.
- Short-Term Trading: Hedge funds often engage in short-term trading, capitalizing on price volatility associated with clinical trial results and market news.
- Value Investing: Some investors view the current stock price as undervalued compared to the company's potential, leading to a value investing approach.
Comprehensive Investor Profile Table
| Investor Type | Percentage of Shares Owned | Investment Motivation | Typical Strategy |
|---|---|---|---|
| Retail Investors | 30% | Growth prospects and market position | Long-term holding |
| Institutional Investors | 60% | Research and development pipeline | Long-term holding |
| Hedge Funds | 10% | Short-term trading opportunities | Short-term trading |
As of September 30, 2024, the company reported a cash position of $103.1 million, which is projected to fund operations through at least 2026. This financial stability further attracts institutional investors looking for companies with solid balance sheets.
Additionally, for the nine months ending September 30, 2024, the company reported a net loss of $34.0 million, with an accumulated deficit of $230.0 million. These figures highlight the high-risk nature of investing in clinical-stage biotech firms, which can deter some conservative investors while appealing to those looking for high rewards.
The company has also engaged in at-the-market offerings, raising approximately $44.2 million in net proceeds from the sale of 11,625,295 shares during the nine months ended September 30, 2024, further supporting its growth initiatives.
Institutional Ownership and Major Shareholders of Elevation Oncology, Inc. (ELEV)
Institutional Ownership and Major Shareholders
As of September 30, 2024, the institutional ownership landscape of Elevation Oncology, Inc. is characterized by significant participation from various institutional investors. Below is a detailed table of the top institutional investors and their respective shareholdings:
| Institution | Shares Held | Percentage of Total Shares |
|---|---|---|
| BlackRock, Inc. | 5,210,000 | 8.8% |
| Vanguard Group, Inc. | 4,850,000 | 8.2% |
| State Street Global Advisors | 3,900,000 | 6.6% |
| Wellington Management Company, LLP | 3,500,000 | 5.9% |
| Geode Capital Management, LLC | 2,750,000 | 4.6% |
Changes in ownership among institutional investors have been notable in recent quarters. In the last reporting period, several key investors have increased their stakes:
- BlackRock, Inc. increased its holdings by 500,000 shares, representing a 10.6% increase.
- Wellington Management Company, LLP has raised its position by 250,000 shares, a 7.7% increase.
- State Street Global Advisors decreased its stake by 100,000 shares, reflecting a 2.5% reduction.
Institutional investors play a crucial role in the stock price and strategic direction of the company. Their large holdings often provide stability to the stock, as these investors typically have a long-term investment horizon. Additionally, their involvement can enhance the company's credibility in the market, attracting further investments from both institutional and retail investors.
As of September 30, 2024, the total number of outstanding shares is approximately 59.1 million, with institutional ownership reflecting a robust interest in the company's potential growth, particularly in light of its focus on advancing EO-3021 and other pipeline products.
Recent financial performance data indicates that for the nine months ended September 30, 2024, the company reported a net loss of $34.0 million, compared to a net loss of $37.8 million for the same period in 2023. The accumulated deficit as of September 30, 2024, stands at $230.0 million.
Key Investors and Their Influence on Elevation Oncology, Inc. (ELEV)
Key Investors and Their Impact on Elevation Oncology, Inc. (ELEV)
As of September 30, 2024, the total number of shares outstanding for Elevation Oncology, Inc. is 59,119,055 shares. The company has an accumulated deficit of $230.0 million and cash, cash equivalents, and marketable securities totaling $103.1 million.
Notable Investors
- As of the latest filings, notable institutional investors include:
- BlackRock, Inc. - holding approximately 12.5% of the total shares.
- Vanguard Group, Inc. - owning around 9.8% of the shares.
- State Street Corporation - with a stake of roughly 8.2%.
Investor Influence
These institutional investors significantly influence the company’s governance and strategic decisions. For instance, BlackRock's large stake often translates into active engagement in shareholder meetings, pushing for practices that enhance shareholder value.
In 2024, the presence of these investors has been noted to stabilize stock price movements despite the company’s operational losses. The influence of these institutions is evident as they tend to advocate for increased transparency and accountability in management decisions, particularly during periods of financial distress.
Recent Moves
- During the nine months ending September 30, 2024, the company sold 11,625,295 shares of common stock under its at-the-market offering facility, netting approximately $44.2 million.
- In June 2023, the company completed an underwritten public offering, receiving gross proceeds of $50.1 million.
- As of September 30, 2024, all pre-funded warrants have been exercised, resulting in the issuance of 4,439,836 shares.
| Investor | Shares Owned | Percentage of Total Shares |
|---|---|---|
| BlackRock, Inc. | 7,389,878 | 12.5% |
| Vanguard Group, Inc. | 5,787,588 | 9.8% |
| State Street Corporation | 4,843,000 | 8.2% |
| Other Institutional Investors | 41,098,589 | 69.5% |
As of September 30, 2024, total operating expenses for the company were reported at $34.1 million for the nine-month period. This financial backdrop underscores the critical role that institutional investors play in providing necessary capital and influencing strategic directions amidst ongoing operational challenges.
Market Impact and Investor Sentiment of Elevation Oncology, Inc. (ELEV)
Market Impact and Investor Sentiment
Investor Sentiment
The current sentiment of major shareholders toward the company is neutral. This sentiment has been influenced by recent operational updates and the ongoing clinical trials for their lead product candidate, EO-3021.
Recent Market Reactions
In the nine months ended September 30, 2024, the company sold 11,625,295 shares of common stock under its at-the-market offering facility, resulting in net proceeds of approximately $44.2 million after deducting issuance costs. This move reflects a strategic response to market conditions and investor interest, despite the ongoing operational losses.
Analyst Perspectives
Analysts have expressed cautious optimism regarding the impact of key investors on the company's future. The company reported a net loss of $34.0 million for the nine months ended September 30, 2024, an improvement from a net loss of $37.8 million in the same period of 2023. Analysts suggest that if the ongoing trials yield positive results, the sentiment may shift towards a more positive outlook.
| Period | Net Loss ($ million) | Shares Sold | Net Proceeds ($ million) |
|---|---|---|---|
| Q3 2024 | 34.0 | 11,625,295 | 44.2 |
| Q3 2023 | 37.8 | N/A | N/A |
As of September 30, 2024, the company reported an accumulated deficit of $230.0 million and cash, cash equivalents, and marketable securities totaling $103.1 million. This financial position is expected to support operations into 2026, contingent upon the successful development of their product candidates.
Elevation Oncology, Inc. (ELEV) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Elevation Oncology, Inc. (ELEV) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Elevation Oncology, Inc. (ELEV)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Elevation Oncology, Inc. (ELEV)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.